Alzheimer’s disease
Conditions
Interventions
Placebo group:Placebo
Experimental group:anthocyanin complex preparations
Sponsors
Aerospace Central Hospital
Eligibility
Sex/Gender
Male
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Male and female aged 50 to 85 years; 2. Mild-to-Moderate AD, i.e.the MMSE score 11-26; 3. Meeting the diagnostic criteria for AD by the NINCDS-ADRDA(1984); 4. Sufficient visual and auditory resolution acceptable neuropsychological tests; 5. There is a certain level of education, read simple texts and write simple sentences; 6. A stable caregiver; 7. Single therapy was initiated on memantine during the tresearch periodand the patient was agreed that the treatment of memantine remained unchanged for three months during the study; 8. Signed the inform consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have dementia caused by other factors: including VaD, Parkinson's disease, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, epilepsy, chronic subdural hematoma and multiple sclerosis, severe head trauma with persistent neurological deficits or abnormal brain structure known; 2. Patients who have suffered from cerebrovascular disease, thyroid disease, vitamin B12 or folate deficiency, anemia or severe malnutrition, severe heart, liver, lung, kidney and other organ disease affecting the central nervous system dysfunction; cerebral vascular disease where the evidence in single or multiple vascular territories, and cognitive decline associated with brain infarction important parts, including the angular gyrus, thalamus, basal forebrain, the anterior cerebral artery territory back to the brain, multiple basal ganglia infarcts, white matter ischemic changes involving extensive white matter region least a full 25% or more; 3. Allergies , Aricept or hydrochloric acid piperidine derivatives allergy; 4. Taking cholinergic or anticholinergic drugs and drugs that affect cognitive function at the same period; 5. Patients who have suffered from depression, schizophrenia and other mental illness; 6. Alcohol, long-term use of antipsychotics; 7. Patients who can not coordinate with cognitive function tests.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cognitive ability;Activities of daily living;Mentality;MoCA; | — |
Secondary
| Measure | Time frame |
|---|---|
| Clinical Global Impression (CGI); | — |
Countries
China
Contacts
Public ContactWang Peifu
Aerospace Central Hospital
Outcome results
None listed